Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott Sells 1,462 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott sold 1,462 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $28.39, for a total value of $41,506.18. Following the transaction, the director now directly owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Progyny Trading Down 0.8 %

PGNY opened at $28.38 on Tuesday. Progyny, Inc. has a 1-year low of $23.90 and a 1-year high of $44.95. The stock’s fifty day simple moving average is $28.52 and its 200 day simple moving average is $34.14. The stock has a market cap of $2.70 billion, a PE ratio of 46.52, a price-to-earnings-growth ratio of 1.85 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The business had revenue of $278.08 million for the quarter, compared to analysts’ expectations of $289.41 million. During the same quarter in the prior year, the business earned $0.18 EPS. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. Equities analysts forecast that Progyny, Inc. will post 0.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PGNY shares. BTIG Research reduced their price target on Progyny from $50.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 10th. KeyCorp cut Progyny from an “overweight” rating to a “sector weight” rating in a research note on Friday, May 10th. Canaccord Genuity Group dropped their price objective on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Barclays dropped their price objective on Progyny from $48.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, May 13th. Finally, Truist Financial dropped their price objective on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.11.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PGNY. International Assets Investment Management LLC increased its position in Progyny by 352,414.2% during the 4th quarter. International Assets Investment Management LLC now owns 5,876,411 shares of the company’s stock worth $218,485,000 after buying an additional 5,874,744 shares during the period. Farallon Capital Management LLC bought a new position in Progyny during the 1st quarter worth $22,608,000. Vanguard Group Inc. increased its position in Progyny by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 8,157,604 shares of the company’s stock worth $277,522,000 after buying an additional 565,160 shares during the period. Wellington Management Group LLP bought a new position in Progyny during the 4th quarter worth $14,608,000. Finally, Norges Bank acquired a new stake in shares of Progyny during the 4th quarter worth $14,198,000. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.